AustarBio Announces Strategic Collaborations with Multiple Partners to Advance Innovative Drug R&D and Industrialization

On December 19, 2025, a seminar on new drug research and development and industrialization, jointly organized by Baiyun Investment Group and Blue Bay Venture Capital, was successfully held at Baiyun Investment Tower in Guangzhou. During the event, Thousand Oaks Biopharmaceuticals signed four major strategic cooperation agreements with leading biopharmaceutical companies including InxMed, Weijinbai'ao, Ractigen Therapeutics, and WizBio/Sudavi Bio.

Baiyun District Outlines a Grand Blueprint to Build a High Ground for the Biomanufacturing Industry

At the beginning of the event, Zhang Yingjiao, Deputy General Manager of Guangzhou Baiyun Industry Investment Group Co., Ltd., delivered the opening speech. First, sheExtended warm welcome to all guests, followed by a systematic introduction of Baiyun District's biomanufacturing industry planning and development strategy.

She pointed out that the biomanufacturing industry, as a typical representative of new quality productive forces, has become a focal point of strategic competition among global powers. In response to the strategic deployments at the provincial and municipal levels, Baiyun District of Guangzhou City is actively accelerating the development of the biomanufacturing industry as an important component of its "6+6+X" modern industrial cluster. The district has released the "Three-Year Action Plan for Accelerating the High-Quality Development of the Biomanufacturing Industry in Baiyun District, Guangzhou City (2026-2028)." As a state-owned capital operation platform specializing in industrial carrier construction, equity investment, and industrial services, Baiyun Investment Group is leveraging an industrial empowerment system based on "policy + space + capital + services." By fully utilizing Baiyun District's comprehensive locational and industrial advantages—including a complete beautiful health industry chain, significant cluster effects, and proximity to end-user markets—the group is committed to building an all-in-one innovative service platform for biomanufacturing. This platform will integrate policy support, financial empowerment, talent cultivation, enterprise incubation, and technology validation, helping to establish a "Baiyun Model" for the development of a globally competitive biomanufacturing industry. It aims to contribute more state-owned enterprise strength to regional industrial upgrading and high-quality economic growth. The concentrated implementation of multiple strategic cooperation initiatives marks both a significant achievement in industrial chain resource integration and a key step in driving collaborative industrial upgrading. Moving forward, Baiyun Investment Group will continue to provide comprehensive support for corporate innovation and development. Experts, scholars, and outstanding entrepreneurs from across China are warmly welcomed to guide our work, invest in Baiyun, and achieve mutual success in the Greater Bay Area.

Industrial Platform Empowers Innovation, Thousand Oaks Facilitates Ecosystem Development

Deng Jianxin, Chairman of Blue Bay Venture Capital, reviewed the decade-long cooperation with Dr. Luo Shun, Chairman of Thousand Oaks. He emphasized,Thousand Oaks' business model has evolved from a单一的培养基供应和CDMO服务，Upgraded to an ecosystem that empowers the entire innovative pharmaceuticals industry.He said, "Our dream is to make the best medicines in the world available in China, and Baiyun District is the most suitable place to realize this dream." He believes that Baiyun District not only has mature urban infrastructure but also sufficient room for development, making it an excellent place for entrepreneurship, a blessed land for starting businesses, and a hotbed for achieving great undertakings. He looks forward to Thousand Oaks settling in Baiyun as soon as possible, taking the lead as a trailblazer and locomotive, bringing more good partners to develop and start businesses in Baiyun, and turning Baiyun into a new highland for China's biopharmaceutical manufacturing.

Dr. Shun Luo, Chairman of Thousand Oaks, expressed gratitude for the support from Baiyun Investment Group, Blue Bay Venture Capital, and all partners. He pointed out that Thousand Oaks not only deeply cultivates in the biopharmaceutical field but also actively expands into broader bio-manufacturing, including new biotech food. He believes that we are currently witnessing a peak in China's new drug creation, and the realization of value in innovative drugs lies precisely in industrialization, which aligns with Thousand Oaks' strategic positioning.

"The innovation we see today must ultimately be grounded in industrial development, which is the inherent logic behind all of our collaborations," said Dr. Luo Shun."Thousand Oaks is committed to being a driver and enabler of this process, with the goal of helping China become the world's largest and most powerful leader in the industrialization of biopharmaceuticals."He added that today's signing is just the beginning, and the road ahead requires the long-term joint efforts of all partners.

The salon brought together numerous industry experts and entrepreneurs to engage in in-depth discussions on topics such as the underlying logic of new drug development, the construction of industrial ecosystems, and future development trends.

InxMedDr. Wang Zaiqi, CEO, made an important point: Tumors are a complex ecosystem, and the key to treatment is not simply killing tumor cells but disrupting the microenvironment they rely on for survival.He emphasized the importance of integrated innovation and ecological cooperation, believing that China has globally leading core competitiveness in chemical synthesis, antibody research and development, and production platforms.

Vijing BoaoDr. Chen Su, CEOBreakthrough Progress Introduced for VG712, a Globally Innovative Drug Under Development. This drug can specifically and rapidly eliminate existing exhausted and diseased T-cell populations in the human body, rebooting normal immune function and thereby restoring spontaneous anti-tumor capabilities in cancer patients. In completed human trials, this innovative mechanism has achieved clinical cure effects in some advanced cancer patients, demonstrating remarkable efficacy and earning Fast Track designation from the U.S. FDA.

In addition to tumors, the immune reboot mechanism brought by VG712 is also expected to provide breakthrough therapies in various difficult-to-treat major diseases such as organ transplant rejection, autoimmune diseases, and AIDS. The drug is currently undergoing the final phase of clinical research before market approval and has established in-depth collaborations with multiple top research institutions in China and the United States to accelerate its market entry.

RactigenDr. Li Longcheng, CEO, shared innovative strategies for unlocking "undruggable" targets using saRNA technology.He pointed out that saRNA technology activates gene transcription and protein production by targeting the gene promoter region, restoring the normal function of the gene.This technology has a wide range of applications and can be used in multiple fields such as genetic diseases, tumors, cardiovascular diseases, and metabolic diseases, opening a new door for "undruggable" targets.

Shanghai Jianshibai BiotechCEO Dr. Lin Jun shared insights on "Thoughts on the Efficient Development of Innovative Complex Molecules." He pointed out that despite the rapid progress in new drug development and the increasing diversity of therapies — from peptides, bispecific antibodies to ADCs, cell and nucleic acid drugs — current treatments still face clinical challenges such as drug resistance. To address the status quo of innovative drug molecule development, which is becoming "more innovative, more complex, and more challenging,"He proposed three key elements: imagination based on scientific risk-taking, execution power to quickly advance toward the goal, and the construction of an industrial ecosystem for "collaboratively developing good medicines."Lin Jun also introduced that Shanghai Jianshibai Biotech provides one-stop early-stage R&D support ranging from molecular design to drug-likeness evaluation, primarily relying on eight core technology platforms. These include the AI prediction and computational biology platform (GSAI™), antibody discovery and engineering platform (GSPS™), innovative linker payload and conjugation platform (GSLP™), drug-likeness evaluation platform (GSDA™), and other comprehensive technical systems. Finally, he emphasized that the company aims to collaborate with industry partners through an integrated platform to efficiently advance the development of differentiated innovative drugs, fulfilling the corporate mission of "Empowering Better Medicine, United for Humanity."

The successful hosting of this event marks an important milestone on the development path of Thousand Oaks and its partners. Looking ahead, through the deep integration and collaborative innovation of government, industry, academia, research, and capital, a vibrant innovative drug industry cluster is expected to rise rapidly, contributing more to the cause of human health.

Review of Hotspots

Thousand Oaks Biopharmaceuticals Assists Sinovac Pharm in Officially Launching the KXBS001 R&D and Industrialization Project!

Promote Biotech Innovation, Empower Busan's Emerging Industries! Busan Metropolitan City Government Partners with Thousand Oaks Biopharmaceuticals and KCell Biosciences to Sign Strategic Cooperation Memorandum

Thousand Oaks Biopharmaceuticals Passes PAI Inspection for the Fourth Time, Demonstrating Its CDMO Manufacturing, Quality, and Regulatory Submission Strength in Biopharmaceuticals Once Again

Thousand Oaks Biopharmaceuticals Co. Ltd. is a provider of comprehensive solutions for the scaled and compliant production of biopharmaceuticals, with business segments covering the biopharmaceutical CDMO sector, cell culture media, and early-stage research services.

In the biopharmaceutical CDMO sector, Thousand Oaks Biopharmaceuticals can provide a one-stop CMC solution from candidate molecules to clinical and commercial production. Currently, this sector has GMP production bases in Nantong, Jiangsu, and Lingang, Shanghai, offering one-stop R&D and production services for drugs including monoclonal antibodies, bispecific antibodies, fusion proteins, and ADCs.

Cell Culture Media Business Unit: Jianshun Biotech, a leading serum-free cell culture media brand in China. Jianshun Biotech specializes in the R&D, production, and sales of serum-free, personalized, chemically defined cell culture media. It also provides customers with comprehensive upstream solutions, including cell culture process development and scale-up, as well as contract manufacturing of custom media formulations. With cell culture media production facilities in Nantong, Jiangsu; Lanzhou, Gansu; and South Korea, its annual production capacity reaches kiloton levels. Its products and technical services are mainly applied in recombinant proteins, antibody drugs, human/veterinary vaccines, and cell therapy fields.

Early Research Services, Advanced by Ginspire (Shanghai Zhangjiang-based). Ginspire focuses on early research services, offering molecular design, molecular evaluation, molecular optimization, and structure-function characterization for various innovative molecules. By collaborating with clients to develop differentiated innovative molecules or licensing out self-developed molecules on demand, the company evaluates and optimizes from multiple dimensions such as structure-function, pharmacology, efficacy, and drug-likeness, increasing the success rate of complex innovative molecule development and more efficiently advancing selected molecules to the next stage of development.